Congressional commission warns of US pharma dependence on China’s innovation

Advertisement

The National Security Commission on Emerging Biotechnology warned in a Nov. 18 brief that China is working to control the pharmaceutical supply chain, from manufacturing to drug discovery, and that U.S. drugmakers’ growing licensing deals with Chinese biotechs are deepening American dependence.

The commission, a congressional body, said China published a pharmaceutical-focused follow-on to its 15th Five-Year Plan in September that frames the industry as a national security priority. The document sets 2030 goals for more first-in-class drugs, higher industry revenue and global sales and more high-revenue companies, names more than 300 technical methods and products to prioritize and supports Chinese biotechs seeking commercialization abroad, according to the commission.

The commission analyzed 57 deals between the 15 largest drugmakers operating in the U.S. and 42 Chinese biotechs from January 2023 to October 2026. It found up-front payments rising and deals increasingly based on preclinical data, as well as escalating structures that move from single-asset out-licensing to multi-asset deals and then co-development agreements around a Chinese company’s discovery platform. It also described “NewCo” structures, in which a Chinese company licenses an asset to a U.S. investor-backed company, as redirecting U.S. capital toward the Chinese industry.

“If this trend continues, Chinese pharmaceutical companies will be able to box out U.S. competitors and leave American patients vulnerable should the CCP decide to cut off the flow of lifesaving treatments,” the commission wrote. It pointed to China’s October proposal to restrict exports of certain next-generation biopharmaceutical technologies, including proprietary drug discovery platforms, with exemptions for specified licensing agreements. The restrictions are not final.

The brief comes as drugs from Chinese laboratories reach U.S. regulators. The FDA this month rejected Summit Therapeutics’ ivonescimab, a lung cancer drug invented in China, after it failed to show a statistically significant survival benefit.

U.S. reliance on China for the drug supply chain is a longer-running concern. Generic drugs rely primarily on India (35%) and China (27%) for their active ingredients, while the U.S. accounts for only 12% of generic drug production. ASHP has said the most immediate patient care risk from supply chain disruption is shortages of sterile injectable generics, which have thin margins. HHS’ Administration for Strategic Preparedness and Response, Commerce and the Department of War are assessing the industrial base for pharmaceutical key starting materials, and the administration is seeking to move production of 86 essential medicines to the U.S. within 18 months.

Advertisement

Next Up in Pharmacy

Advertisement